Conclusions
toxicity
ADVERSE EVENTS
Although the treatment‐related adverse events were manageable, the combination of weekly irinotecan and S‐1 did not have the expected effect.
The combination of weekly irinotecan and S‐1 was not superior to single‐agent therapy in terms of ORR, although the toxicity profile was as expected.This combination did not yield the expected effects and may not be a candidate regimen for future phase III trials.
